Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Hepion Pharmaceuticals, Inc. (HEPA : OTC)

• Company Description    Hepion Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis and chronic hepatitis virus infection. The Company's lead drug candidate CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Hepion Pharmaceuticals Inc., formerly known as ContraVir Pharmaceuticals Inc., is based in Edison, New Jersey. Number of Employees: 0

• Price / Volume Information    Yesterday's Closing Price: $0.07 Daily Weekly Monthly 20 Day Moving Average: 127,784 shares Shares Outstanding: 10.93 (millions) Market Capitalization: $0.77 (millions) Beta: 1.59 52 Week High: $0.16 52 Week Low: $0.04 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 27.41% 22.01% 12 Week -84.74% -87.46% Year To Date -99.70% -99.71%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 55 Madison Ave Suite 400- PMB# 4362 - Morristown,NJ 07960 USA ph: 732-902-4000 fax: 732-902-4100 info@hepionpharma.com http://www.hepionpharma.com

• General Corporate Information    Officers John Brancaccio - Interim Chief Executive Officer; Chief Financial O Michael Purcell - Director Timothy Block - Director Kaouthar Lbiati - Director Arnold Lippa - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 426897401 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 10.93 Most Recent Split Date: 3.00 (0.02:1) Beta: 1.59 Market Capitalization: $0.77 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.35 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 92.32% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/25 - - 12/31/24 - -2,595.57 09/30/24 - -812.56 ROA 03/31/25 - -372.50 12/31/24 - -193.09 09/30/24 - -207.31 Current Ratio 03/31/25 - 6.75 12/31/24 - 0.51 09/30/24 - 1.30 Quick Ratio 03/31/25 - 6.75 12/31/24 - 0.51 09/30/24 - 1.30 Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Pre-Tax Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Book Value 03/31/25 - 0.20 12/31/24 - -25.57 09/30/24 - -18.12 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - 0.00 12/31/24 - - 09/30/24 - - Debt-to-Capital 03/31/25 - 0.00 12/31/24 - - 09/30/24 - -

Powered by Zacks Investment Research ©